FY2029 EPS Estimates for GH Research Raised by HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Stock analysts at HC Wainwright raised their FY2029 EPS estimates for shares of GH Research in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.13 per share for the year, up from their prior estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06.

A number of other analysts have also commented on the company. Canaccord Genuity Group decreased their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. Cantor Fitzgerald started coverage on GH Research in a report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price target for the company. Finally, Stifel Nicolaus raised their price objective on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $30.60.

GH Research Stock Up 10.9 %

Shares of GHRS opened at $10.41 on Thursday. The business’s fifty day moving average is $10.66 and its 200 day moving average is $9.19. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50. The stock has a market cap of $541.61 million, a P/E ratio of -13.18 and a beta of 0.93.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after acquiring an additional 3,092 shares during the last quarter. AdvisorShares Investments LLC increased its position in shares of GH Research by 15.4% in the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after purchasing an additional 4,806 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in GH Research in the fourth quarter valued at approximately $44,000. Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after acquiring an additional 8,641 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in GH Research during the fourth quarter worth about $117,000. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).